Fidelity SPDR Advertisement
Home > Boards > Free Zone > User's Groups > Mohacsy's Safe Portfolio Member Forum

Orphan Drug Status doesn't assure FDA approval of

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
n4807g Member Profile
Member Level 
Followed By 30
Posts 27,185
Boards Moderated 0
Alias Born 07/08/03
160x600 placeholder
U.S. Stocks Surge; Dow Rises 200 Points
The U.S. stock market moved sharply higher on Thursday, as investors cheered upbeat manufacturing data from eurozone and better-than-expected earnings from Caterpillar Inc, 3M Co and General Motors.
Top Equities Stories Of The Day
Tech Stocks Rise Ahead Of Microsoft, Amazon Earnings
Correction to AT&T Earnings Preview Story
Microsoft Braces for Another Nokia Hit--Earnings Preview
Stifel Financial to Hire Two Former Merrill Lynch Advisers
Kyle Bass: Still Bullish on GM, Despite Recall Issue -CNBC
Procter & Gamble Looking at Margins, Brands--Earnings Preview
U.S. Stock Futures Hover Near Even
Safran Revenue Rises on Sustained Demand for Jet Engines
n4807g Member Level  Monday, 04/23/12 12:16:00 PM
Re: FullBoogie post# 60301
Post # of 68580 
Orphan Drug Status doesn't assure FDA approval of the compound being evaluated, it confers certain marketing advantages and tax credits should the drug be approved.

Like most small biotechs CYTR will succeed or fail on the technology they employ. In CYTR's case the delivery system. The near term future of INNO-206 will be clear when they report interim findings of their ongoing 2b trial.

Like all biotechs this is a speculative investment, but I've watched many companies with similar strategies do well. The preliminary data look promising (no guarantee) but as I said in my previous post Abraxane uses Albumin as the entry vehicle in tumors and CYTR uses the same concept.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist